Hanall Biopharma Co., Ltd., a prominent pharmaceutical company based in South Korea, has been actively engaged in the research, development, and international sale of a diverse range of pharmaceutical products. As of July 21, 2026, the company continues to focus on advancing its pipeline of innovative treatments aimed at addressing various medical conditions.
Hanall Biopharma is currently developing several key products. Among these is HL161, an anti-FcRn antibody designed to treat autoimmune diseases. The company is also working on HL036, an anti-TNF bio ophthalmic solution intended for the treatment of dry eye disease. In the oncology sector, Hanall Biopharma is advancing HL186 and HL187, which target recurrent and intractable cancers. Additionally, HL040 is being developed for the treatment of hypertension-dyslipidemia, while HL068 focuses on hypertension. HL018 is another significant project aimed at treating obesity. Furthermore, IM156 is under development as a potential treatment for cancer.
Founded in 1973 and headquartered in Seoul, South Korea, Hanall Biopharma has established itself as a key player in the pharmaceutical industry. The company is listed on the Korea Exchange Stock Market, reflecting its significant presence in the sector. As of July 15, 2026, the close price of Hanall Biopharma’s stock was 52,800 KRW. The company’s market capitalization stands at 2,685,312,696,320 KRW, indicating its substantial market value.
Despite its robust pipeline and market presence, Hanall Biopharma’s financial metrics reveal some challenges. The price-to-earnings ratio is notably negative at -546.17, suggesting that the company is currently not generating profits. This could be attributed to the high costs associated with research and development in the pharmaceutical industry. Over the past year, the company’s stock has experienced significant volatility, with a 52-week high of 73,000 KRW on May 26, 2026, and a 52-week low of 25,550 KRW on August 3, 2025.
Hanall Biopharma’s commitment to innovation and its strategic focus on developing treatments for critical health conditions underscore its potential for future growth. The company’s efforts to bring new therapies to market could eventually translate into improved financial performance and shareholder value. For more information, stakeholders and interested parties can visit the company’s official website at www.hanall.co.kr .
